Ceftazidime--a new extended-spectrum cephalosporin.
65 patients with serious infections, including 25 with septicaemia, were treated with ceftazidime, a new extended-spectrum cephalosporin. 80% of the infection were cured by the antibiotic. 11 of 12 infected patients who had malignant disease or were otherwise immunocompromised responded satisfactorily to ceftazidime; 7 of these 12 had infections caused by Pseudomonas aeruginosa. The serum half-life of ceftazidime was 1.9 h in a patient with normal renal function. After a 1 g intravenous dose the antibiotic was present in pus, sputum, and bile in therapeutic concentrations. The antibiotics should prove a useful and non-toxic alternative to the aminoglycosides.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy*; D002442:Ceftazidime; D002511:Cephalosporins / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy; D014946:Wound Infection / Q000188:drug therapy
D002511:Cephalosporins; D002442:Ceftazidime